MetLife Investment Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-17,692
| Closed | -$47.2K | – | 2871 |
|
|
2022
Q1 | $47.2K | Sell |
17,692
-6,754
| -28% | -$18K | ﹤0.01% | 2680 |
|
|
2021
Q4 | $106K | Buy |
24,446
+14,566
| +147% | +$63.1K | ﹤0.01% | 2387 |
|
|
2021
Q3 | $50.3K | Sell |
9,880
-16,228
| -62% | -$82.6K | ﹤0.01% | 2532 |
|
|
2021
Q2 | $165K | Buy |
26,108
+20,846
| +396% | +$132K | ﹤0.01% | 2269 |
|
|
2021
Q1 | $40.7K | Sell |
5,262
-9,764
| -65% | -$75.5K | ﹤0.01% | 2286 |
|
|
2020
Q4 | $98.4K | Hold |
15,026
| – | – | ﹤0.01% | 2227 |
|
|
2020
Q3 | $99.9K | Sell |
15,026
-12,276
| -45% | -$81.6K | ﹤0.01% | 2211 |
|
|
2020
Q2 | $227K | Hold |
27,302
| – | – | ﹤0.01% | 1831 |
|
|
2020
Q1 | $209K | Hold |
27,302
| – | – | ﹤0.01% | 1674 |
|
|
2019
Q4 | $227K | Hold |
27,302
| – | – | ﹤0.01% | 1913 |
|
|
2019
Q3 | $201K | Hold |
27,302
| – | – | ﹤0.01% | 1939 |
|
|
2019
Q2 | $306K | Buy |
27,302
+9,012
| +49% | +$101K | ﹤0.01% | 1772 |
|
|
2019
Q1 | $197K | Hold |
18,290
| – | – | ﹤0.01% | 1993 |
|
|
2018
Q4 | $276K | Hold |
18,290
| – | – | ﹤0.01% | 1732 |
|
|
2018
Q3 | $338K | Hold |
18,290
| – | – | ﹤0.01% | 1782 |
|
|
2018
Q2 | $418K | Buy |
18,290
+4,831
| +36% | +$110K | ﹤0.01% | 1515 |
|
|
2018
Q1 | $383K | Buy |
13,459
+1,860
| +16% | +$52.9K | ﹤0.01% | 1538 |
|
|
2017
Q4 | $245K | Buy |
+11,599
| New | +$245K | ﹤0.01% | 1823 |
|